UK markets close in 8 hours 12 minutes

Grifols, S.A. (GRFS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.39-0.09 (-1.39%)
At close: 04:00PM EDT
6.39 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.48
Open6.42
Bid6.38 x 400
Ask6.41 x 400
Day's range6.29 - 6.44
52-week range5.30 - 12.15
Volume963,534
Avg. volume2,166,237
Market cap5.41B
Beta (5Y monthly)0.68
PE ratio (TTM)63.90
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date03 Jun 2021
1y target estN/A
  • Reuters

    Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

    MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.

  • Bloomberg

    Grifols Plans First Bond Sale Since Short Seller Attack

    (Bloomberg) -- Grifols SA is seeking to issue a new bond, in what would be its first debt deal since coming under attack from a short seller in January.Most Read from BloombergUS Slams Strikes on Russia Oil Refineries as Risk to Oil MarketsUS Core CPI Tops Forecasts Again, Likely Delaying Fed Rate CutsChinese Cement Maker Halted After 99% Crash in 15 MinutesBond Trader Places Record Futures Bet on Eve of Inflation DataApple’s India iPhone Output Hits $14 Billion in China ShiftThe Barcelona-based

  • Reuters

    Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake

    Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday. Grifols did not specify the amount due next year. Since January, the Spanish drug maker's debt sustainability has been questioned by short seller Gotham City Research.